The trefoil peptide TFF1 inhibits the growth of the human gastric adenocarcinoma cell line ags

Journal of Pathology

Volumn 188, Issue 3, 1999, Pages 312-317

  Calnan, Denis P ^a   Westley, Bruce R ^b   May, Felicity E B ^b   Floyd, David N ^a   Marchbank, Tania ^a   Playford, Raymond J ^a  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Cell growth; Gastric cancer; Growth inhibition; pS2; TFF domain

Indexed keywords

TREFOIL PEPTIDE;

ADULT; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL LINE; CELL PROLIFERATION; CELL STRUCTURE; DIMERIZATION; DNA SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA;

EID: 0032980531     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199907)188:3<312::AID-PATH360>3.0.CO;2-P     Document Type: Article

References (27)

1. Wright NA, Hoffmann W, Otto WR, Rio M-C, Thim L. Rolling in the clover: trefoil factor family (TFF)-domain peptides, cell migration and cancer. FEBS Lett 1997; 408: 121-123.
2. Rio M-C, Bellocq JP, Gairard B, et al. Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the oestrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci U S A 1987; 84: 9243-9247.
3. Rio M-C, Bellocq JP, Daniel JY, et al. Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science 1988; 241: 705-708.
4. Wright NA, Poulsom R, Stamp G, et al. Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology 1993; 104: 12-20.
5. Henry JA, Bennett MK, Piggott NH, Levett DL, May FEB, Westley BR. Expression of the pNR-2-pS2 protein in diverse human epithelial tumours. Br J Cancer 1991; 64: 677-682.
6. Luqmani Y, Bennett C, Paterson I, et al. Expression of the pS2 gene in normal, benign and neoplastic human stomach. Int J Cancer 1989; 44: 806-812.
7. Muller W, Borchard F. pS2 protein in gastric carcinoma and normal gastric mucosa: association with clinicopathological parameters and patient survival. J Pathol 1993; 171: 263-269.
8. Machado J-C, Carneiro F, Blin N, Sobrinho-Simoes M. Pattern of pS2 protein expression in premalignant and malignant lesions of gastric mucosa. Eur J Cancer Prevention 1996; 5: 169-179.
9. Lefebvre O, Chenard M-P, Masson R, et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 1996; 274: 259-262.
10. Marchbank T, Westley BR, May FEB, Calnan DP, Playford RJ. Dimerisation of human pS2 (TFF1) plays a key role in its protective/healing effects. J Pathol 1998; 185: 153-158.
11. Williams R, Elia G, Stamp GWH, Oates T, Wright NA, Lalani E-N. Characterization of monoclonal antibodies raised to C-terminal peptides of pS2: a major trefoil peptide and motility factor expressed in adenocarcinomas and regions of mucosal injury. Hum Pathol 1996; 27: 1259-1266.
12. Barranco SC, Townsend CM Jr, Casartelli C, et al. Establishment and characterisation of an in vitro model system for human adenocarcinoma of the stomach. Cancer Res 1983; 43: 1703-1709
13. Jeon KW, Koh TJ, Wu D-C, Wang C. Human spasmolytic polypeptide gene expression is regulated by serum in the human gastric carcinoma cell line KATO 111. Gastroenterology 1997; 112(Suppl): A881.
14. Efstathiou JA, Noda M, Rowan A, et al. Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin - catenin complexes in human colon carcinoma cells. Proc Natl Acad Sci USA 1998; 95: 3122-3127.
15. Poulsom R. Trefoil peptides. In: Goodlad RA, Wright NA, eds. Baillière's Clinical Gastroenterology: Cytokines and Growth Factors in Gastroenterology. Vol. 10. London: Baillière Tindall, 1996: 113-134.
16. Rio M-C, Chenard M-P, Wolf C, et al. Induction of pS2 and hSP genes as markers of mucosal ulceration of the digestive tract. Gastroenterology 1991; 100: 375-379.
17. Mashimo H, Wu C, Podolsky DK, Fishman MC. Impaired defence of intestinal mucosa in mice lacking intestinal trefoil factor. Science 1996; 274: 262-265.
18. Playford RJ, Marchbank T, Goodlad RA, et al. Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc Natl Acad Sci U S A 1996; 93: 2137-2142.
19. Dignass A, Lynch-Devaney K, Kindon H, Thim L, Podolsky DK. Trefoil peptides promote epithelial migration through a transforming growth factor β independent pathway. J Clin Invest 1994; 94: 376-383.
20. Chinery R, Bates PA, De A, Freemont PS. Characterisation of the single copy trefoil peptides intestinal trefoil factor and pS2 and their ability to form covalent dimers. FEBS Lett 1995; 357: 50-54.
21. Kida N, Yoshimura T, Mori K, Hayashi K. Hormonal regulation of synthesis and secretion of pS2 protein relevant to growth of human breast cancer cells. Cancer Res 1989; 49: 3494-3498.
22. Hoosein NM, Thim L, Jorgensen KH, Brattain MG. Growth stimulatory effect of pancreatic spasmolytic polypeptide on cultured colon and breast tumor cells. FEBS Lett 1989; 247: 303-306.
23. Otto WR, Rao J, Cox HM, et al. Effects of pancreatic spasmolytic polypeptide (PSP) on epithelial cell function. Eur J Biochem 1996; 235: 64-72.
24. Jeffrey GP, Oates PS, Wang TC, Babyatski MW, Brand SJ. Spasmolytic polypeptide: a trefoil peptide secreted by rat gastric mucus cells. Gastroenterology 1994; 106: 336-345.
25. Babyatsky MW, deBeaumont M, Thim L, Podolsky DK. Oral trefoil peptides protect against ethanol and indomethacin induced gastric injury in rats. Gastroenterology 1996; 110: 489-497.
26. Theisinger B, Welter C, Seitz G, et al. Expression of the breast cancer associated gene pS2 and the pancreatic spasmolytic polypeptide gene (hSP) in diffuse type of stomach carcinoma. Eur J Cancer 1991; 27: 770-773.
27. Williams R, Stamp GW, Gilbert C, Pignatelli M, Lalni EN. pS2 transfection of murine adenocarcinoma cell line 410.4 enhances dispersed growth pattern in a 3-D collagen gel. J Cell Sci 1996; 109: 63-71.